FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration. Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
I started receiving subcutaneous administration of VELCADE four weeks ago and overall I have felt ok since then. Side effects have been minimum and I tolerate it with no major problems so far. The only battle I have been in is constipation. Subcutaneous VELCADE is working well for me!
ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Dr. Noopur Raje Discusses Her Research Interests in MM, Including Subcutaneous VELCADE
step 1: get the correct diagnosis
step 3: Initial treatment options
back
print
related articles
I started receiving subcutaneous administration of VELCADE four weeks ago and overall I have felt ok since then. Side effects have been minimum and I tolerate it with no major problems so far. The only battle I have been in is constipation. Subcutaneous VELCADE is working well for me!